Chip-Man Technologies Announces Collaboration with TCS CellWorks
News Jun 15, 2006
Chip-Man Technologies Limited and TCS CellWorks have announced a technology collaboration, whereby Chip-Man Technologies’ Cell-IQ® continuous cell culturing platform will be used with TCS CellWorks’ AngioKit model.
Terry Cartwright, CEO, TCS CellWorks commented, "TCS CellWorks produces information-rich in vitro models based on cultured human cells for drug discovery and functional analysis."
He continued, "We are delighted with the results obtained in collaboration with Chip-Man Technologies and their new Cell-IQ cell analysis system."
"This raises our ability to track cell proliferation, migration and differentiation within a complex co-culture model to a new level."
Cell-IQ is designed to enable the subtle changes in cellular growth and tubule formation to be recorded and monitored kinetically.
Juha Korpinen, CEO, Chip-Man Technologies added, "We welcome the opportunity to work with TCS CellWorks. They have a range of products to which Cell-IQ will bring additional value."
Cell-IQ is a continuous cell culturing platform, optimized for the real-time analysis of morphological and physiological events in living cells, co-cultures, primary cells and monolayer tissue models.
The fully integrated ‘machine vision’ technology is designed to control all detection and environmental systems.
As a result the Cell-IQ learns to identify, follow and measure morphological change in individual cells without traditional labels or dyes.
TCS CellWorks’ AngioKit offers a cell-based system using solely human cell-lines, for quantitatively assessing both pro- and anti-angiogenic agents.
The kit is provided in 24-well plate format and is suitable for low volume screening applications.
Angiogenesis is the multi-step process by which new blood vessels develop from existing vasculature.
It is the subject of intense research activity at present since the controlled modulation of angiogenesis offers the possibility of therapeutic approaches to several important diseases including cardiovascular disease, arthritic disease, cancer, psoriasis and diabetic retinopathy.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE